WO2012038825A3 - Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1) - Google Patents

Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1) Download PDF

Info

Publication number
WO2012038825A3
WO2012038825A3 PCT/IB2011/002397 IB2011002397W WO2012038825A3 WO 2012038825 A3 WO2012038825 A3 WO 2012038825A3 IB 2011002397 W IB2011002397 W IB 2011002397W WO 2012038825 A3 WO2012038825 A3 WO 2012038825A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tff1
inhibitors
trefoil factor
cancer
Prior art date
Application number
PCT/IB2011/002397
Other languages
French (fr)
Other versions
WO2012038825A2 (en
Inventor
Peter E. Lobie
Johanna Kate Perry
Original Assignee
Auckland Uniservices Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Limited filed Critical Auckland Uniservices Limited
Publication of WO2012038825A2 publication Critical patent/WO2012038825A2/en
Publication of WO2012038825A3 publication Critical patent/WO2012038825A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates generally to the use of inhibitors of TTF1 to increase radiosensitivity of tumors and other cells. The invention provides methods of inhibiting proliferation or survival of a tumor cell; methods of treating, delaying the progression of, preventing a relapse of, or alleviating a symptom of a cancer or other neoplastic condition; methods increasing sensitivity of a tumor cell to radiotherapy; methods of enhancing or supplementing an anti-cancer therapy in a subject that is receiving or has been administered radiotherapy; and methods of inhibiting one or more activity or function of a TFF1 - stimulated cancer stem cell.
PCT/IB2011/002397 2010-09-21 2011-09-21 Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1) WO2012038825A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38497210P 2010-09-21 2010-09-21
US61/384,972 2010-09-21
US39296910P 2010-10-14 2010-10-14
US61/392,969 2010-10-14

Publications (2)

Publication Number Publication Date
WO2012038825A2 WO2012038825A2 (en) 2012-03-29
WO2012038825A3 true WO2012038825A3 (en) 2012-07-26

Family

ID=45874210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002397 WO2012038825A2 (en) 2010-09-21 2011-09-21 Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1)

Country Status (1)

Country Link
WO (1) WO2012038825A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119519A1 (en) * 1999-12-23 2002-08-29 Reinhard Ebner Trefoil domain-containing polynucleotides, polypeptides, and antibodies
US20080199455A1 (en) * 2006-10-03 2008-08-21 Lobie Peter E Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
US20090022708A1 (en) * 2004-12-22 2009-01-22 Lobie Peter E Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
US20090304700A1 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals, Ltd. Conformation specific antibodies that bind trefoil factors
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119519A1 (en) * 1999-12-23 2002-08-29 Reinhard Ebner Trefoil domain-containing polynucleotides, polypeptides, and antibodies
US20090022708A1 (en) * 2004-12-22 2009-01-22 Lobie Peter E Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
US20080199455A1 (en) * 2006-10-03 2008-08-21 Lobie Peter E Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
US20090304700A1 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals, Ltd. Conformation specific antibodies that bind trefoil factors
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALCER-KUBICZEK ET AL.: "Coordinate Late Expression of Trefoil Peptide Genes (pS2/TFF1 and ITF/TFF3) in Human Breast, Colon, and Gastric Tumor Cells Exposed to X-Rays.", MOLECULAR CANCER THERAPEUTICS., vol. 1, no. 6, April 2002 (2002-04-01), pages 405 - 415 *

Also Published As

Publication number Publication date
WO2012038825A2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX344355B (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers.
PH12016500841A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
SG10201902380SA (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ706836A (en) Methods of treating cancer
MX365074B (en) Cancer therapy using cldn6 target-directed antibodies in vivo.
MX2020003719A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer.
MX360092B (en) Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane.
PH12014501880A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
TW200621240A (en) Cancer treatments
MX2012009030A (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
MX2010006991A (en) Therapeutic cancer treatments.
WO2011159685A3 (en) Inhibition of wdr5 interaction with its binding partners and therapeutic methods
MX2012008958A (en) Neuregulin antagonists and use thereof in treating cancer.
WO2013019945A3 (en) Method for selection of chemotherapeutic agents for adenocarcinoma cancer
WO2009105217A3 (en) Complement inhibitors as therapeutic agents for treatment of cancer
NZ609594A (en) Eph receptor expression in tumor stem cells
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
WO2012087115A8 (en) Cancer targeting using carbonic anhydrase isoform ix inhibitors
WO2012038825A3 (en) Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1)
WO2009061770A3 (en) Method of inhibiting abcg2 and related treatments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11826476

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11826476

Country of ref document: EP

Kind code of ref document: A2